Acetyl Gastric Inhibitory Peptide (human)  (Synonyms: Human N-acetyl GIP)

Acetyl Gastric Inhibitory Peptide (human) is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) can be used for research of diabetes, insulin resistance and obesity^[1][2][3].

Acetyl Gastric Inhibitory Peptide (human) induces cyclic adenosine 3'5' monophosphate (cAMP) production with an EC₅₀ value of 1.9 nM in Chinese hamster lung fibroblast cells transfected with the human GIP receptor^[1].
Acetyl Gastric Inhibitory Peptide (human) (10^-13-10^-8 nM) shows potent effect at stimulating insulin release compared to the native GIP in BRIN-BD11 cells^[1].
Acetyl Gastric Inhibitory Peptide (human) improves glucose intolerance, type 2 diabetes, beta-cell glucose insensitivity, insulin resistance and reduced insulin secretion^[2].
Acetyl Gastric Inhibitory Peptide (human) has metabolic stability and hypoglycemic and insulin modulating activities of two fatty acid derivatized N-terminally acetylated GIP analogs were evaluated in in vitro and in vivo^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Acetyl Gastric Inhibitory Peptide (human) (25 nmol/kg; i.p.; single dose) shows resistance to plasma dipeptidylpeptidase IV degradation, resulting in enhanced biological activity and improved antidiabetic potential in vivo^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

5025.60

C₂₂₈H₃₄₀N₆₀O₆₇S

299898-33-2

Ac-Tyr-Ala-Glu-Gly-Thr-Phe-Ile-Ser-Asp-Tyr-Ser-Ile-Ala-Met-Asp-Lys-Ile-His-Gln-Gln-Asp-Phe-Val-Asn-Trp-Leu-Leu-Ala-Gln-Lys-Gly-Lys-Lys-Asn-Asp-Trp-Lys-His-Asn-Ile-Thr-Gln

Ac-YAEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQ

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. O'Harte FP, et al. Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. Diabetologia. 2002 Sep;45(9):1281-91.  [Content Brief]

  [2]. Gault Victor A, et al. GIP peptide analogues for treatment of diabetes, insulin resistance and obesity: World Intellectual Property Organization, WO2005082928[P]. 2005-12-01.

  [3]. O'Harte, et al. Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function: World Intellectual Property Organization, WO2007028632[P].2007-03-15.